Pharmaceutical

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).

Jan 9, 2024 - 18:00
EC approves Pfizer’s Talzenna combo for prostate cancer treatment
The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).
Read the original article

Tags:

Previous Article

BIOS Health to launch precision medicine centre in California, US

Next Article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

Opinion: STAT+: A California court is setting a dangero...

Feb 13, 2024

STAT+: It was a turbulent year for the business of health tech. 3 trends to watch in 2024

STAT+: It was a turbulent year for the business of heal...

Jan 2, 2024

Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

Why Biogen is purposefully becoming more risk averse, a...

Oct 20, 2023